JAK3/TEC Kinase Pathways Are Active In Alopecia Areata Lesions, And Their Inhibition With Ritlecitinib Prevents αCD3/αCD28+IL-2 Induced Immune Privilege Collapse In Healthy Hair Follicles Ex Vivo
September 2025
in “
Journal of the American Academy of Dermatology
”
New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide → Studysummary Ritlecitinib may help treat alopecia areata by protecting hair follicles.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study investigates the role of JAK3/TEC kinase pathways in alopecia areata lesions and evaluates the efficacy of Ritlecitinib, a JAK inhibitor, in preventing immune privilege collapse in healthy hair follicles. The research demonstrates that these pathways are active in alopecia areata and that Ritlecitinib effectively inhibits the αCD3/αCD28+IL-2 induced collapse of immune privilege in hair follicles ex vivo. This suggests that targeting these pathways with Ritlecitinib could be a promising therapeutic approach for treating alopecia areata.
